Ghrelin administration in comatose patients after cardiac arrest is safe, causes no serious adverse events relatable to ghrelin use and it improves functional recovery in these patients.
ID
Bron
Verkorte titel
Aandoening
Postanoxic encephalopathy, postanoxic, coma after cardiac arrest, ghrelin administration, neuroprotection
Ondersteuning
Clinical neurophysiology
Drienerlolaan 5
7522NB Enschede
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
We aim to measure safety and efficacy of intravenous treatment with acyl-ghrelin to promote cerebral recovery in comatose patients after cardiac arrest. Safety will be monitored throughout hospitalization and during follow-up using all AEs reported, and by interim analyses by an independent DSMB. Efficacy will be measured by the primary outcome measure, i.e. functional recovery as measured by the Cerebral Performance Category (CPC) scale at six months after cardiac arrest.
Achtergrond van het onderzoek
Rationale: Approximately half of all comatose patients after cardiac never regains
consciousness because of severe postanoxic encephalopathy. The other half may be left
with cognitive or motor disturbances. Currently, there is no treatment to promote cerebral
recovery. Treatment with acyl-ghrelin improved functional recovery under experimental in
vivo and in vitro conditions, and decreased histologically measured neuronal damage.
Ghrelin has been tested in over one hundred human studies, including studies in healthy
volunteers and patients with cardiopulmonary diseases, neuro-endocrine diseases,
psychiatric diseases, and neurodegenerative diseases. Serious adverse events were
extremely rare and difficult to attribute to ghrelin administration
Objective: First, we aim to estimate safety and efficacy of intravenous treatment with acyl-
ghrelin to promote cerebral recovery in comatose patients after cardiac arrest. Second, we
will estimate efficacy of ghrelin to modify case fatality, time to awaken, long term (cognitive)
outcome, and cardiovascular outcomes, including blood pressure, treatment with inotropic
medication, treatment with vasopression and cardiac biomarkers.
Study design: This will be a phase 2 multicenter, double blind, placebo controlled
randomized clinical trial.
Study population: Comatose patients (GCS score of 8 or lower) after cardiac arrest and
successful cardiopulmonary resuscitation, admitted to intensive care units of participating
hospitals, will be included within 12 hours after resuscitation.
Intervention Intravenous treatment with acylated ghrelin 600micrg twice daily for 1 week vs.
placebo.
Main study parameters/endpoints: The primary outcome measure will be functional
outcome as expressed as the score of the cerebral performance category (CPC) at 6
months.
Doel van het onderzoek
Ghrelin administration in comatose patients after cardiac arrest is safe, causes no serious adverse events relatable to ghrelin use and it improves functional recovery in these patients.
Onderzoeksopzet
Case fatality
Time to awaken
Cardiovasculair measures: day 0-7
Venous blood samples: day 0, 1, 2, 3
CPC scores: after 3 en 6 months
Neuropsychological examination: after 12 months
Gastric residual volume: day 0-7
Onderzoeksproduct en/of interventie
Intravenous treatment with acylated ghrelin 600micrg twice daily for 1 week vs. placebo.
Algemeen / deelnemers
J. Hofmeijer
Wagnerlaan 55
Arnhem 6815 AD
The Netherlands
jhofmeijer@rijnstate.nl
Wetenschappers
J. Hofmeijer
Wagnerlaan 55
Arnhem 6815 AD
The Netherlands
jhofmeijer@rijnstate.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
In order to be eligible to participate in this study a subject must meet the following criteria:
- Age ≥18 years
- Out of hospital cardiac arrest
- Successful cardiopulmonary resuscitation
- Return of spontaneous circulation ¡Ü12 hours ago
- GCS score on admission ≤ 8 or suspected coma in patients who are sedated
- Admission to intensive care unit
- Hemodynamic and respiratory stability as determined by the treating intensive care physician, with the minimum requirement of mean arterial pressure > 65 mmHg. Treatment with inotropes, vasopressors or IABP is allowed.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Age <18 years
- A known progressive neurological disease
- Expected death within 48 hours
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7155 |
| NTR-old | NTR7354 |
| Ander register | ZonMW : 951 05001 |